Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
https://doi.org/10.17650/1818-8346-2016-11-2-37-39
Abstract
Patients with myelofibrosis in blast-phase commonly have a median overall survival of only 3–6 months. Given the older median age of onset and heavy pretreatment, intensive chemotherapy often is not appropriate and has low efficacy with high toxicity. Ruxolitinib (a JAK1/2 inhibitor) has provided significant clinical benefits in patients with chronic phase myelofibrosis. We report our experience of treating blastphase myelofibrosis patients with the combination therapy of ruxolitinib plus low dose mercaptopurine or low-dose cytarabine. The cases presented here demonstrated the feasibility and tolerability of combination continuous ruxolitinib treatment with mercaptopurine or low-dose cytarabine for patients with blast-phase myelofibrosis. The efficacy of these combination regimens is encouraging.
About the Authors
M. S. Fominykh
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2nd Sovetskaya St., Saint Petersburg, 191024, Russia
Russian Federation
Russian Federation
V. A. Shuvaev
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2nd Sovetskaya St., Saint Petersburg, 191024, Russia
Russian Federation
Russian Federation
I. S. Martynkevich
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2nd Sovetskaya St., Saint Petersburg, 191024, Russia
Russian Federation
Russian Federation
L. B. Polushkina
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2nd Sovetskaya St., Saint Petersburg, 191024, Russia
Russian Federation
Russian Federation
V. Yu. Udal’eva
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2nd Sovetskaya St., Saint Petersburg, 191024, Russia
Russian Federation
Russian Federation
K. M. Abdulkadyrov
Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological Agency; 16 2nd Sovetskaya St., Saint Petersburg, 191024, Russia
Russian Federation
Russian Federation
References
1. Mesa R. A., Li C. Y., Ketterling R. P. et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105(3):973–7.
2. Tam C. S., Nussenzveig R. M., Popat U. et al. The natural history and treatment outcome of blast phase BCR-ABL negative myeloproliferative neoplasms. Blood 2008;112(5):1628– 37. DOI: 10.1182/ blood-2008‑02‑138230.
3. Абдулкадыров К. М., Шуваев В. А., Мартынкевич И. С. Критерии диагностики и современные методы лечения первичного миелофиброза. Вестник гематологии 2013;9(3):44–78. [Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. Criteria for diagnosis and modern methods of treatment of primary myelofibrosis. Vestnik gematologii = Journal of Hematology 2013; 9(3):44-78. (In Russ.)].
4. Verstovsek S., Mesa R. A., Gotlib J. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799–807. DOI: 10.1056/ NEJMoa1110557.
5. Mwirigi A., Galli S., Keohane C. et al. Combination therapy with ruxolitinib plus 5- azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast- phase myeloproliferative neoplasms. Br J Haematol 2014;167(5):714–6. DOI: 10.1111/bjh. 13046.
6. Devillier R., Raffoux E., Rey J. et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol 2016;172(4):628–30. DOI: 10.1111/bjh. 13516.
7. Mascarenhas J., Heaney M. L., Najfeld V. et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase(MPN-BP): formal recommendations from the postmyeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res 2012;36(12):1500–4. DOI: 10.1016/j. leukres. 2012.08.013.
Review
For citations:
Fominykh M.S., Shuvaev V.A., Martynkevich I.S., Polushkina L.B., Udal’eva V.Yu., Abdulkadyrov K.M. Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis. Oncohematology. 2016;11(2):37-39. (In Russ.) https://doi.org/10.17650/1818-8346-2016-11-2-37-39
Views:
9792
Email this article 